Alnylam Pharmaceuticals, Inc. (ALNY) News

Alnylam Pharmaceuticals, Inc. (ALNY)

Today's Latest Price: $123.02 USD

1.68 (-1.35%)

Updated Nov 23 4:00pm

Add ALNY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Filter ALNY News Items

ALNY News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest ALNY News From Around the Web

Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Arcutis Announces Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

Arcutis receives a boost with positive seborrheic dermatitis study data Arcutis Biotherapeutics Inc. (ARQT) announced positive top line data from its seborrheic dermatitis study. This Phase 2 clinical trial seeks to assess the potential of ARQ-154 in treating seborrheic dermatitis. According to the data, Roflumilast foam 0.3% dispensed once daily...

Avisol Capital Partners on Seeking Alpha | October 2, 2020

Global Antisense and RNAi Therapeutics Market Shows Strong Growth with Leading Players are Astellas Pharma Inc, Quark, Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma

DBMR has added a new report titled Antisense and RNAi therapeutics market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are

OpenPR | October 1, 2020

Global Antisense and RNAi Therapeutics Market Sees a Faster Rebound in the Era of COVID-19 | Industry Size, Share, Growth Factors, Development Strategy, Top Leaders-Astellas Pharma Inc, Quark, Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Tekmira

DBMR has added a new report titled Global Antisense and RNAi Therapeutics Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken

OpenPR | September 30, 2020

Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). ILLUMINATE-B is now the seventh Phase 3 study of an RNAi therapeutic that has yielded

Business Wire | September 30, 2020

Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, will host an “RNAi Roundtable” webinar today at 12:00 p.m. ET, which will focus on progress across its ATTR amyloidosis programs. The Company will discuss the potential for a biannual subcutaneous dosing regimen for vutrisiran, as well as discuss ongoing Phase 3 development for patisiran and vutrisiran across the APOLLO-B, HELIOS-A, and HELIOS-B studies. The Company also annou

Business Wire | September 3, 2020

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually: Citi 15th Annual BioPharma Virtual Conference on Thursday, September 10, 2020 at 10:45 am ET Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 9:30 am ET Cantor Virtual Global Healthcare Conference on Wednesday, September 16,

Business Wire | September 2, 2020

Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2020 and reviewed recent business highlights. “In the second quarter of 2020, the world experienced unprecedented challenges as it continued to confront the COVID-19 pandemic. While the pandemic continues in some countries and states, our global commercialization strategy is now enabling some customer-fac

Business Wire | August 6, 2020

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

A Top Contender in the Race for a NASH Drug Drops Out

French biotech Genfit, which had been expected to bring one of the first drugs to market to treat nonalcoholic steatohepatitis, said it is getting out of the race altogether.

Yahoo | July 23, 2020

Alnylam to Webcast Conference Call Discussing Second Quarter 2020 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2020 on Thursday, August 6, 2020, before the U.S. financial markets open.

Yahoo | July 23, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6481 seconds.